Stryker Q2 adj. EPS hits $5.75, beating $3.49 estimate
Stryker (NYSE: SYK) reported second-quarter 2026 adjusted earnings per share of $5.75, surpassing analyst consensus estimates of $3.49 by 64.76 percent. This result marks an 83.71 percent year-over-year increase from $3.13 in the prior-year period. Consolidated net sales rose 9.42 percent to $6.589 billion, narrowly exceeding the $6.579 billion estimate. The strong performance reflects robust operational execution and expanded margins despite modest revenue growth.
How this was made
The 30-second read
Why it matters
The key trade inputs are the magnitude of the adjusted EPS beat, the margin expansion (adjusted operating margin +170 bps), and the narrowed FY2026 organic sales and adjusted EPS outlook.
Market read
A strong Q2 adjusted EPS beat plus a guidance floor increase can re-rate near-term earnings expectations and reduce perceived downside risk.
What to watch
The guidance revision only lifts the lower bound by $0.05 while the upper bound stays at $15.10, implying limited upside surprise potential versus prior expectations.
Background
Stryker’s Q2 performance is framed as recovery momentum after a cyber incident reported in March 2026.
Ticker impact
Stryker reported Q2 adjusted EPS of $5.75 versus $3.49 consensus and raised FY2026 adjusted EPS guidance to $14.95-$15.10.
Likely positive reaction and continued momentum if investors focus on margin expansion and the narrowed guidance range.
The article provides concrete Q2 adjusted EPS and sales figures versus estimates, and a specific FY2026 guidance range revision (lower end raised, upper end unchanged), which are direct drivers for earnings expectations and valuation.
Market effects
Signals improving profitability dynamics for medical technology peers, particularly around margin expansion and execution.
US and international sales both grew, suggesting demand resilience across geographies.
FX is described as slightly favorable, which can influence how investors model international revenue translation for medtech.
Counterpoint
The revenue beat is modest versus the earnings outperformance, so the stock may be sensitive if margin tailwinds prove temporary.
Key entities
- companyStryker
Reported Q2 adjusted EPS and sales versus consensus, and updated FY2026 guidance range.
- executiveKevin A. Lobo
CEO and Chair cited resilience and innovation cadence as drivers of regained momentum.
